Arrivo BioVentures Raises $45 Million to Advance Treatment for Major Depression Disorder

Why It Matters:

This funding allows Arrivo BioVentures to move into late-stage development for its SP-624 compound, which has shown promising results in alleviating depressive symptoms in female subjects. The treatment has the potential to address the significant gender disparity in MDD.

The Details:

• Arrivo BioVentures raises $45 million in funding, bringing the total raised to $100 million.

• The company plans to advance its SP-624 compound through clinical trials.

• SP-624 selectively activates the SIRT6 enzyme, an epigenetic mechanism that modulates gene expression, metabolism, and DNA repair.

• Arrivo's Phase 2 study indicates that female subjects on SP-624 experienced early and robust alleviation of depressive symptoms.

• The funding will also enable Arrivo to explore the use of SP-624 in other diseases and pursue regulatory approval for MDD treatment.

Conclusion:

Arrivo BioVentures secures additional funding to further develop its innovative treatment for major depression disorder, with the potential to improve women's mental health.